Can Singulair help hives?
Chronic urticaria (CU) is a condition characterized by recurring, itchy hives and angioedema that significantly impacts quality of life. While antihistamines are the first line of treatment, a subset of patients fails to achieve adequate control, necessitating alternative or adjunctive therapies. Leukotriene antagonists (LTAs), primarily montelukast (Singulair), have been explored for their role in managing CU due to their anti-inflammatory properties. This article examines the pathophysiology of leukotrienes in urticaria, the mechanism of action of LTAs, and evidence from clinical studies on their effectiveness as an adjunct treatment for CU.
Introduction
Chronic urticaria is a debilitating skin condition marked by recurrent hives lasting longer than six weeks. Current treatment approaches include second-generation H1-antihistamines, corticosteroids, and biologics like omalizumab. However CU patients show limited response to antihistamines alone, necessitating exploration of adjunct treatments. Leukotrienes, which play a central role in inflammation, have been implicated in CU pathogenesis, particularly in cases where histamine pathways are insufficiently responsive. LTAs, such as montelukast, are thus considered as a complementary option for refractory CU.
Pathophysiology of Leukotrienes in Chronic Urticaria
Leukotrienes, a group of eicosanoids derived from arachidonic acid, are potent mediators of inflammation. The production of cysteinyl leukotrienes (LTB4, LTC4, LTD4, and LTE4) in response to allergens and other inflammatory stimuli contributes to vasodilation, vascular permeability, and smooth muscle contraction. In CU, these compounds exacerbate inflammation and recruit immune cells, enhancing the urticarial response. Studies have identified elevated leukotriene levels in patients with antihistamine-refractory CU, suggesting an enhanced leukotriene-mediated inflammatory response in this subgroup.
Mechanism of Action of Leukotriene Antagonists
Leukotriene antagonists, such as montelukast, act by selectively inhibiting the binding of cysteinyl leukotrienes to their receptors, notably the CysLT1 receptor. This blockade reduces leukotriene-induced inflammatory effects, including decreased vascular permeability and attenuated immune cell recruitment. LTAs also suppress pro-inflammatory cytokine release, which may contribute to the reduction of urticarial symptoms.
Clinical Evidence of Leukotriene Antagonists in Chronic Urticaria
- Monotherapy vs. Combination Therapy
Studies on LTAs as monotherapy for CU have shown mixed results, with some indicating only modest symptom relief. However, as adjunct therapy with antihistamines, LTAs have demonstrated more consistent efficacy. In patients unresponsive to standard antihistamines, adding montelukast has been reported to improve urticaria control and decrease flare frequency. - Randomized Controlled Trials
Clinical trials comparing montelukast with placebo as add-on therapy to antihistamines have generally shown favorable outcomes. A meta-analysis of multiple trials noted significant reductions in urticarial symptoms and itching intensity in patients receiving montelukast in addition to H1-antihistamines. These findings highlight the potential of LTAs to enhance therapeutic efficacy, especially in patients with CU unresponsive to antihistamines alone. - Long-Term Safety and Efficacy
LTAs have shown a favorable safety profile, particularly for long-term use. Adverse effects are generally mild, with headache and gastrointestinal discomfort being the most common. Montelukast’s safety profile contrasts with other adjunct treatments, such as corticosteroids, which pose risks with prolonged use.
Potential Limitations and Considerations
While LTAs offer promise, their efficacy is not universal across all CU patients. Additionally, genetic differences and variations in leukotriene receptor expression may influence response rates. Future research may benefit from identifying biomarkers to predict LTA responsiveness and conducting trials on different leukotriene receptor antagonists to explore potential benefits beyond montelukast.
Conclusion
Compared to antihistamines alone, the combination of a leukotriene receptor antagonist (Singulair) with antihistamines probably modestly reduce hives activity, itch and hive severity, and it may improve health related quality of life.
Add on Singulair probably have limited to no difference in overall adverse events, but no randomized trial reported on any neuropsychiatric events.
These results indicate the clinical utility of adding on leukotriene receptor antagonists to antihistamines for managing chronic hives.
If you suffer from chronic hives that are unresponsive to antihistamines, speak to your allergy doctor about adding Singulair to help your hives.
Stepwise approach to Chronic Urticaria (Chronic Hives)
Xolair (Omalizumab) for Chronic Urticaria
Singulair psychiatric side effects; a large study

